Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 12/20 | 1.00 |
| ▸ | CA12 | O43570 | 5/20 | 0.66 |
| ▸ | CA1 | P00915 | 5/20 | 0.66 |
| ▸ | CA2 | P00918 | 5/20 | 0.66 |
| ▸ | CA6 | P23280 | 5/20 | 0.66 |
| ▸ | CA7 | P43166 | 5/20 | 0.66 |
| ▸ | CA9 | Q16790 | 5/20 | 0.66 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.66 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.66 |
| ▸ | CA5A | P35218 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | HTR1A | P08908 | 1/20 | 0.66 |
| ▸ | CA4 | P22748 | 1/20 | 0.66 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.66 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.66 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.66 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
| ▸ | CA3 | P07451 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18426052 | 0.86 | CISD1 (0.76) | CISD1CA12CA1CA2CA6 | |
| SCHEMBL11788810 | 0.85 | CISD1 (0.74) | CISD1CA12CA1CA2CA6 | |
| SCHEMBL11789259 | 0.84 | CISD1 (0.73) | CISD1CA12CA1CA2CA6 | |
| SCHEMBL11875494 | 0.84 | CISD1 (0.73) | CISD1CA12CA1CA2CA6 | |
| SCHEMBL1716052 | 0.82 | CISD1 (1.00) | CISD1CA12CA1CA2CA6 | |
| SCHEMBL11708093 | 0.82 | CISD1 (0.69) | CISD1CA12CA1CA2CA6 | |
| SCHEMBL2873972 | 0.82 | CISD1 (0.69) | CISD1CA12CA1CA2CA6 | |
| SCHEMBL11787100 | 0.81 | CISD1 (0.68) | CISD1CA12CA1CA2CA6 | |
| SCHEMBL10963109 | 0.81 | CISD1 (0.68) | CISD1CA12CA1CA2CA6 | |
| Furosemide SCHEMBL29406913 | 0.80 | CISD1 (1.00) | CISD1CA12CA1CA2CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | claimed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | claimed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | F9, F12, HDAC9 | CISD1 1891/4885CA12 449/4885CA1 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.